癌症患者的静脉血栓栓塞预防与治疗:ASCO指南更新
本指南更新基于2018年11月1日至2022年6月6日发表的随机对照试验,对围手术期血栓预防和静脉血栓栓塞治疗两个问题进行系统评价。结果显示,阿哌沙班和利伐沙班可作为癌症手术后延长药物性血栓预防的选择(弱推荐);阿哌沙班也可作为静脉血栓栓塞治疗的选择(高质量证据,强推荐)。
要点
- 阿哌沙班和利伐沙班被新增为癌症手术后延长药物性血栓预防的选择,推荐强度为弱推荐。
- 阿哌沙班被新增为静脉血栓栓塞治疗的选择,证据质量为高质量,推荐强度为强推荐。
- 术后试验存在重要局限性,但提示这两种口服抗凝药在研究背景下安全有效。
核心结论
- 阿哌沙班和利伐沙班被新增为癌症手术后延长药物性血栓预防的选择,推荐强度为弱推荐。
- 阿哌沙班被新增为静脉血栓栓塞治疗的选择,证据质量为高质量,推荐强度为强推荐。
研究设计与样本
- 通过ASCO的信号更新方法识别可能改变实践的临床试验后,对围手术期血栓预防和静脉血栓栓塞治疗两个指南问题进行更新系统评价。
- 检索PubMed和Cochrane Library,纳入2018年11月1日至2022年6月6日发表的随机对照试验。
主要发现
- 五项随机对照试验提供了导致2019年推荐改变的信息。
- 两项随机对照试验探讨直接Xa因子抑制剂(利伐沙班或阿哌沙班)用于手术后延长血栓预防,每项术后试验均有重要局限性,但提示这两种口服抗凝药在研究背景下安全有效。
- 另有三项随机对照试验探讨阿哌沙班用于静脉血栓栓塞治疗,阿哌沙班有效降低复发性静脉血栓栓塞风险,且大出血风险低。
关键数值与推荐
- 阿哌沙班和利伐沙班被新增为癌症手术后延长药物性血栓预防的选择,推荐强度为弱推荐。
- 阿哌沙班被新增为静脉血栓栓塞治疗的选择,证据质量为高质量,推荐强度为强推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 每项术后试验均有重要局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To conduct an update of the ASCO venous thromboembolism (VTE) guideline. METHODS: After publication of potentially practice-changing clinical trials, identified through ASCO's signals approach to updating, an updated systematic review was performed for two guideline questions: perioperative thromboprophylaxis and treatment of VTE. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) published between November 1, 2018, and June 6, 2022. RESULTS: Five RCTs provided information that contributed to changes to the 2019 recommendations. Two RCTs addressed direct factor Xa inhibitors (either rivaroxaban or apixaban) for extended thromboprophylaxis after surgery. Each of these postoperative trials had important limitations but suggested that these two oral anticoagulants are safe and effective in the settings studied. An additional three RCTs addressed apixaban in the setting of VTE treatment. Apixaban was effective in reducing the risk of recurrent VTE, with a low risk of major bleeding. RECOMMENDATIONS: Apixaban and rivaroxaban were added as options for extended pharmacologic thromboprophylaxis after cancer surgery, with a weak strength of recommendation. Apixaban was also added as an option for the treatment of VTE, with high quality of evidence and a strong recommendation.Additional information is available at www.asco.org/supportive-care-guidelines.
引用
- Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023. PMID: 37075273. doi:10.1200/JCO.23.00294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。